229 related articles for article (PubMed ID: 21824412)
21. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Fillmore CM; Kuperwasser C
Breast Cancer Res; 2008; 10(2):R25. PubMed ID: 18366788
[TBL] [Abstract][Full Text] [Related]
22. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
23. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
24. [Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].
Lu ZQ; Li HG; Zhang HZ; Fan MJ; Shen XM; He XX
Ai Zheng; 2008 Jun; 27(6):575-9. PubMed ID: 18570728
[TBL] [Abstract][Full Text] [Related]
25. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
26. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
Perrone G; Gaeta LM; Zagami M; Nasorri F; Coppola R; Borzomati D; Bartolozzi F; Altomare V; Trodella L; Tonini G; Santini D; Cavani A; Muda AO
PLoS One; 2012; 7(9):e43110. PubMed ID: 23028444
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
28. Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis.
Tomar R; Rakheja G; Verma N; Thakur S; Khurana N; Ghuliani D
Indian J Pathol Microbiol; 2023; 66(2):258-263. PubMed ID: 37077065
[TBL] [Abstract][Full Text] [Related]
29. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.
dos Santos PB; Zanetti JS; Ribeiro-Silva A; Beltrão EI
Diagn Pathol; 2012 Aug; 7():104. PubMed ID: 22894137
[TBL] [Abstract][Full Text] [Related]
30. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
31. The distribution of CD44+/CD24- cancer stem cells in breast cancer and its relationship with prognostic factors.
Cabuk D; Yetimoglu E; Simsek T; Gacar G; Subasi C; Canturk Z; Ercin C; Karaoz E; Uygun K
J BUON; 2016; 21(5):1121-1128. PubMed ID: 27837613
[TBL] [Abstract][Full Text] [Related]
32. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of CD24 and CD44 transcripts in Iranian breast cancer patients.
Liaghati P; Momeni P; Esfandi F; Kholghi Oskooei V; Sattari A; Ghafouri-Fard S; Taheri M
Breast Dis; 2020; 39(3-4):143-148. PubMed ID: 33427725
[TBL] [Abstract][Full Text] [Related]
34. Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway.
Hardt O; Wild S; Oerlecke I; Hofmann K; Luo S; Wiencek Y; Kantelhardt E; Vess C; Smith GP; Schroth GP; Bosio A; Dittmer J
Cancer Lett; 2012 Dec; 325(2):165-74. PubMed ID: 22771536
[TBL] [Abstract][Full Text] [Related]
35. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
36. Stem cell-related markers in primary breast cancers and associated metastatic lesions.
Guler G; Balci S; Costinean S; Ussakli CH; Irkkan C; Suren D; Sari E; Altundag K; Ozisik Y; Jones S; Bacher J; Shapiro CL; Huebner K
Mod Pathol; 2012 Jul; 25(7):949-55. PubMed ID: 22388757
[TBL] [Abstract][Full Text] [Related]
37. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells.
Murohashi M; Hinohara K; Kuroda M; Isagawa T; Tsuji S; Kobayashi S; Umezawa K; Tojo A; Aburatani H; Gotoh N
Br J Cancer; 2010 Jan; 102(1):206-12. PubMed ID: 19997106
[TBL] [Abstract][Full Text] [Related]
38. High GD2 expression defines breast cancer cells with enhanced invasiveness.
Mansoori M; Roudi R; Abbasi A; Abolhasani M; Abdi Rad I; Shariftabrizi A; Madjd Z
Exp Mol Pathol; 2019 Aug; 109():25-35. PubMed ID: 31075227
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer stem cell population in different molecular subtypes of breast cancer.
Gupta P; Singh V; Kumar S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):199-203. PubMed ID: 35068436
[TBL] [Abstract][Full Text] [Related]
40. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
